ArticleJournal of Cancer2016
The Expression of Ubiquitous Mitochondrial Creatine Kinase Is Downregulated as Prostate Cancer Progression.
Article in Journal of Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Platelet CKB as a potential contributor to serum creatine kinase abnormalities and metastasis in cancer patients.Clinical and experimental medicine · 2025Article
- Increased Levels of Oxidative Stress in Human Prostate Intraepithelial Neoplasia and Prostate Cancer: Evidence from 4-Hydroxyneonal Detection and Its Implications.Antioxidants (Basel, Switzerland) · 2025Article
- Targeting Creatine and Creatine Kinase in Cancer: Exploring Potential Therapeutic Strategies.Current drug targets · 2025Review
- Role of creatine shuttle in colorectal cancer cells.Oncotarget · 2023Article
- Mitochondrial creatine kinase 1 regulates the cell cycle in non-small cell lung cancer via activation of cyclin-dependent kinase 4.Respiratory research · 2023Article
- Colorectal polyps increase the glycolytic activity.Frontiers in oncology · 2023Article
- Role of Serum Creatinine Levels in Prognostic Risk Stratification of Prostate Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- An integrative pan-cancer analysis of molecular characteristics and oncogenic role of mitochondrial creatine kinase 1A (CKMT1A) in human tumors.Scientific reports · 2022Article
- Stable Isotope Tracing Uncovers Reduced γ/β-ATP Turnover and Metabolic Flux Through Mitochondrial-Linked Phosphotransfer Circuits in Aggressive Breast Cancer Cells.Frontiers in oncology · 2022Article
- Downregulated miRNA-491-3p accelerates colorectal cancer growth by increasing uMtCK expression.PeerJ · 2022Article
- Mitochondrial creatine kinase 1 in non-small cell lung cancer progression and hypoxia adaptation.Respiratory research · 2021Article
- Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy.Nutrients · 2021Review
- CKMT1B is a potential prognostic biomarker and associated with immune infiltration in Lower-grade glioma.PloS one · 2021Article
- Adenylate Kinase and Metabolic Signaling in Cancer Cells.Frontiers in oncology · 2020Review
- MiR-519b-3p Inhibits the Proliferation and Invasion in Colorectal CancerFrontiers in pharmacology · 2019Article
- The complexity of mitochondrial outer membrane permeability and VDAC regulation by associated proteins.Journal of bioenergetics and biomembranes · 2018Article
- Insights into the Phosphoryl Transfer Mechanism of Human Ubiquitous Mitochondrial Creatine Kinase.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitochondria play crucial roles in cell signaling events, interorganellar communication, aging, cell proliferation and apoptosis, and mitochondrial impairment has been shown to accelerate or modulate cancer progression. Ubiquitous mitochondrial creatine kinase (uMtCK) is predominantly localized in the intermembrane space of mitochondria and catalyzes the reversible exchange of high-energy phosphate between adenosine tri-phosphate (ATP) and phosphocreatine. However, little is known about its expression and function in human prostate cancer progression.
methodWe investigated the expression of uMtCK in 148 prostate carcinoma tissues and matched normal tissue by immunohistochemistry. The expression and localization of uMtCK and hexokinase II, a marker of glycolysis, were examined in prostate carcinoma cell lines using western blot and immunofluorescence.
resultsMtCK expression was significantly lower in high Gleason grade carcinoma compared with normal prostate or low grade carcinoma. Western blot further revealed that uMtCK was highly expressed in LNCaP and 22Rv1 cell lines, as well as in the normal prostate cell line RWPE-1. However, uMtCK expression was almost absent in PC3 and DU145 cell lines, in correlation with absent or mutant p53 expression, respectively. In contrast, hexokinase II was overexpressed in PC3 cells. Moreover, in the low uMtCK expressing cell lines, glycolytic ATP production was increased, whereas mitochondrial ATP production was decreased.
conclusionsThese data suggest that uMtCK is downregulated as prostate cancer progresses in correlation with a metabolic switch in ATP usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.